Books - Proceedings - Chapters - Interviews

2014

Celiac Disease and Non-Celiac Gluten Sensitivity

Luis Rodrigo and Amado Salvador Peña

DOI: http://dx.doi.org/10.3926/oms.223

ISBN: 978-84-942118-2-9

1st editon © 2014 OmniaScience (Omnia Publisher SL)

www.omniascience.com

DL: B-23979-2014

English Translation: Carlos Beirute Lucke, Translator in Chief, CIEC. Translator and Interpreter,

Ministry of Foreign Relations, Costa Rica

CHAPTER 1: Celiac Disease And Non-Celiac Gluten Sensitivity by A.S. Peña, L. Rodrigo, pp 25-44  | http://dx.doi.org/10.3926/oms.236

CHAPTER 3: Perspectives To Take Into Account When Studying Celiac Disease in China and Central America by A. Pérez-Villavicencio, C. Beirute-Lucke, A. S. Peña, pp 61-74  | http://dx.doi.org/10.3926/oms.237

CHAPTER 4: Celiac Disease in El Salvador by M. Cromeyer, R.A. Gutérrez, K. Zaldívar, J. B. A. Crusius, A.S. Peña, pp 75- 88 | http://dx.doi.org/10.3926/oms.231

 

2013

Enfermedad celíaca y sensibilidad al gluten no celíaca
Luis Rodrigo y Amado Salvador Peña
DOI: http://dx.doi.org/10.3926/oms.16
ISBN: 978-84-940234-3-9
1ª edición © 2013 OmniaScience (Omnia Publisher SL)
DL: B-12675-2013

CAPÍTULO 1: ENFERMEDAD CELÍACA Y SENSIBILIDAD AL GLUTEN NO CELÍACA
A.S. Peña, L. Rodrigo pp 25-43
This chapter explains the ttle of the book and highlights the importance of recognizing the Non celiac Gluten Sensitvity. Briefy discuss the topics covered in the diferent chapters within the
context of a new defniton with recent advances in China, Mexico, El Salvador and Costa Rica.
We review the immunological diferences between celiac disease and non-celiac gluten
sensitvity as well as the clinical and pathological diferences among celiac disease, gluten
allergy, gluten sensitvity and non-celiac gluten intolerance.
The physiological and immunological efects that can trigger wheat products are also briefy
summarized without mentoning somatzaton disorders that may apply to some patents with
sensitvity or food intolerance. In this light we describe new concepts over placebo and nocebo.
This new insight suggests the need to incorporate protocols to understand the efects of a
gluten-free diet. It is clear that the two opposing mechanisms, placebo and nocebo may be
important not only when administering drugs but when specifc diets are used as a treatment.
Subsequently, attenton is drawn to the chapters of diagnostc techniques such as celiac disease
serology, endoscopy and histopathology as well as various clinical forms in children and adults.
Finally, we briefy review the diferent and clinically important topics in celiac disease that is
described by authors that are experts in their respectve issues

Capítulo 3. Pérez Villavicencio A, Beirute Lucke C, Peña AS. Enfermedad Celíaca en China y Centroamérica.
En Rodrigo L y Peña AS, editores. Enfermedad celíaca y sensibilidad al gluten no celíaca.
Barcelona, España: OmniaScience; 2013. pp 61-74.
Doi: http://dx.doi.org/10.3926/oms.91
Abstract
Until quite recently it was thought that celiac disease did not exist either in China or in Central
America. The cultivation of rice in China and the cultivation of maize from the Mexican highlands
have respectively been the basis of nourishment in China and Central America. Environmental,
social and cultural changes in these regions allow foreseeing an increase in celiac disease cases.
By way of example, we can ofer the deparasitation of rural populations which contribute to a
change in the TH2 to TH1 predominant intestinal immune response, changes in the intestinal
microbiota mainly in urban areas due to access to antibiotics, change in dietary habits due to the
infuence of “fast foods” and changes in traditional diets based on rice or maize due to the
difusion of diets with a higher gluten content.
It is necessary to analyze the diagnostic difculties in these countries regarding the identifcation
of the disease as well as the techniques involved in its diagnosis. The main limitation of these
studies lies in the absence of duodenal biopsies. Each population where celiac disease is
emerging needs to adjust its array of detection procedures.
It can be concluded that, even if it is true that sensitive and specifc serologic tests for celiac
disease have allowed establishing the prevalence of this disease with greater confdence, it can
be suggested that the priority in these emerging countries is the creation of interdisciplinary
study groups which will decide the specifc protocols for each region.

Capítulo 4. Cromeyer M, Zaldívar K, Crusius JBA, Peña AS. La Enfermedad Celíaca en El Salvador. En Rodrigo L y Peña AS, editores. Enfermedad celíaca y sensibilidad al gluten no celíaca. Barcelona, España:OmniaScience; 2013. p. 75-87.
Doi: http://dx.doi.org/10.3926/oms.137

Celiac disease is insufficiently known in El Salvador. Between July and August of 2012, the
HLA-DQ was genotyped in 35 patients diagnosed with celiac disease and 30 were relatives or in
the diagnostic process. Genomic DNA was extracted from peripheral blood for HLA-DQA1 and
HLA-DQB1 genotyping. Polymerase chain reaction-amplified exon 2 amplicons were generated
for low- to medium resolution typing in a combined, single-stranded conformation
polymorphism heteroduplex assay by a semiautomated electrophoresis and gel-staining method
on the PhastSystem.
The series includes persons aged between 19 and 77 all residing in urban areas. Of the 35
patients with celiac disease (27 women, 8 men), the “gold standard”, biopsy compatible with
CD, was fulfilled in 33. Two have not been biopsied yet. There are 26 (78.8%) positive carriers of heterodimers with risk genotypes. Of those, 15 with HLA-DQ8 (12 women, 3 men), 9 with HLADQ2 only (5 women, 4 men) and 2 women had both HLA-DQ2 and DQ8. Interestingly, 9 (25.7%) persons did not carry the HLA-DQ8 or HLA-DQ2. 17 of 21 relatives (81%) belonging to 7 family groups were carriers of risk alleles.
The results of these studies on HLA-DQ in El Salvador are the first to be published and confirm
the clinical diagnosis of celiac disease.

Chapters - Books 2011


 

 

Chapters - Books 2009

 


 Drugs of Today (Barcelona) 2009, 45 Suppl. B

 An integrated approach to the understanding of Chlamydia Infections: 2009 Update

1. Morré SA, Peña AS.

An integrated approach to the understanding of Chlamydia infections: Introduction to the 2009 update.

Drugs Today (Barc). 2009 Nov;45 Suppl B:3-5.

 

2. Morré SA, Ouburg S, Peña AS, Brand A.

The EU FP6 EpiGenChlamydia Consortium: contribution of molecular epidemiology and host-pathogen genomics to understanding Chlamydia trachomatis-related disease.

Drugs Today (Barc). 2009 Nov;45 Suppl B:7-13.

 

3. Lyons JM, Ouburg S, Morré SA.

An integrated approach to Chlamydia trachomatis infection: the ICTI Consortium, an update.

Drugs Today (Barc). 2009 Nov;45 Suppl B:15-23.

 

4. Smelov V, Quint KD, Pleijster J, Savelkoul PHM, Shalepo K, Shipitsyna E, Domeika M, Gorelov A, Savicheva A, Quint WGV, de Vries HJC, Ouburg S, Morré SA.

Chlamydia trachomatis serovar distributions in Russian men and women: a comparison with Dutch serovar distributions.

Drugs Today (Barc). 2009 Nov;45 Suppl B:33-8.

 

5. van der Ham R, de Vries HJC.

Lymphogranuloma venereum, where do we stand?: clinical recommendations.

Drugs Today (Barc). 2009 Nov;45 Suppl B:39-43.

 

6. Bailey RL, Natividad-Sancho A, Fowler A, Peeling RWW, Mabey DCW, Whittle HC, Jepson AP.

Host genetic contribution to the cellular immune response to Chlamydia trachomatis: Heritability estimate from a Gambian twin study.

Drugs Today (Barc). 2009 Nov;45 Suppl B:45-50.

 

7. Lyons JM, Igietseme JU, Black CM, Morré SA.

 Identification of candidate genes using the murine model of female genital tract infection with Chlamydia trachomatis.

Drugs Today (Barc). 2009 Nov;45 Suppl B:51-9.

 

8. Karimi O, Ouburg S, de Vries HJC, Peña AS, Pleijster J, Land JA, Morré SA.

TLR2 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women.

Drugs Today (Barc). 2009 Nov;45 Suppl B:67-74.

 

9. den Hartog JE, Lyons JM, Ouburg S, Fennema JSA, de Vries HJC, Bruggeman CA, Ito JI, Peña AS, Land JA, Morré SA.

TLR4 in Chlamydia trachomatis infections: knockout mice, STD patients and women with tubal factor subfertility.

Drugs Today (Barc). 2009 Nov;45 Suppl B:75-82.

 

10. Ouburg S, Lyons JM, Land JA, den Hartog JE, Fennema JSA, de Vries HJC, Bruggeman CA, Ito JI, Peña AS, Lundberg PSJ, Morré SA.

TLR9 KO mice, haplotypes and CPG indices in Chlamydia trachomatis infection.

Drugs Today (Barc). 2009 Nov;45 Suppl B:83-93.

 

11. Wang W, Stassen FR, Surcel HM, Öhman H, Tiitinen A, Paavonen J, de Vries HJC, Heijmans R, Pleijster J, Morré SA, Ouburg S.

Analyses of polymorphisms in the inflammasome-associated NLRP3 and miRNA-146A genes in the susceptibility to and tubal pathology of Chlamydia trachomatis infection.

Drugs Today (Barc). 2009 Nov;45 Suppl B:95-103.

 

12. Abdul-Sater AA, Said-Sadier N, Ojcius DM, Yilmaz Ö, Kelly KA.

      Inflammasomes bridge signaling between pathogen identification and the immune response.

      Drugs Today (Barc). 2009 Nov;45 Suppl B:105-12.

 

13. Peña AS, Karimi O, Crusius JBA.

A new avenue to investigate: the autophagic process. From Crohn's disease to Chlamydia.

Drugs Today (Barc). 2009 Nov;45 Suppl B:113-7.

 

14. Lyons JM, Morré SA, Land JA.

Aspects of reproductive biology that influence the distribution and spread of Chlamydia trachomatis within the female genital tract: a new paradigm.

Drugs Today (Barc). 2009 Nov;45 Suppl B:119-24.

 

15. King M, Poya H, Rao J, Natarajan S, Butch AW, Aziz N, Kok S, Chang MH, Lyons JM, Ault K, Kelly KA.

CXCL13 expression in Chlamydia trachomatis infection of the female reproductive tract. Drugs Today (Barc). 2009 Nov;45 Suppl B:125-34.

 

16. Verweij SP, Bax CJ, Quint KD, Quint WGV, van Leeuwen AP, Peters RPH, Oostvogel PM, Mutsaers JA, Dörr PJ, Pleijster J, Ouburg S, Morré SA.

Significantly higher serologic responses of Chlamydia trachomatis B group serovars versus C and I serogroups. Drugs Today (Barc). 2009 Nov;45 Suppl B:135-40.

 

17. Pospischil A.

 From disease to etiology: historical aspects of Chlamydia-related diseases in animals and humans.

Drugs Today (Barc). 2009 Nov;45 Suppl B:141-6.

 

18. Verminnen K, Vanrompay D.

Chlamydophila psittaci infections in turkeys: overview of economic and zoonotic importance and vaccine development.

Drugs Today (Barc). 2009 Nov;45 Suppl B:147-50.

 

19. Pannekoek Y, Visser C, Duim B, Heddema ER.

Chlamydophila psittaci infections in The Netherlands.

Drugs Today (Barc). 2009 Nov;45 Suppl B:151-7.

 

20. Boelen E, Steinbusch HWM, Bruggeman CA, Stassen FRM.

The inflammatory aspects of Chlamydia pneumoniae-induced brain infection.

Drugs Today (Barc). 2009 Nov;45 Suppl B:159-64.

 

21. Vainas T, Sayed S, Bruggeman CA, Stassen FRM.            

Exploring the role of Chlamydia pneumoniae in cardiovascular disease: a narrative review.

Drugs Today (Barc). 2009 Nov;45 Suppl B:165-72.

 

22. Rabasseda X, Morré SA, Ouburg S.

Bioinformatic approaches to the study of Chlamydial diseases.

Drugs Today (Barc). 2009 Nov;45 Suppl B:173-87.

 

Chapters - Books 2007


Amado Salvador Peña y Joaquín Hinojosa del Val
Nuevas fronteras en el tratamiento medico de la enfermedad de Crohn.
Hay que invertir la piramide terapeutica? En “Hacia la integración en el tratamiento de las enfermedades digestivas”.

I Jornada Médico-Quirúrgica Hospital General Universitario de Valencia 4 Mayo 2007 Pp: 83-89
Editores: Enrique Medina Chuliá & José Vicente Roig Vila
Edita: Consorcio Hospital General Universitario de Valencia
Diseño: Viqui Sanahuja

Joaquín Hinojosa del Val & Amado Salvador Peña
Tratamiento médico de la enfermedad de Crohn en relación con el patrón clínico
y con la gravedad del brote. En “Hacia la integración en el tratamiento de las enfermedades digestivas”.

I Jornada Médico-Quirúrgica Hospital General Universitario de Valencia 4 Mayo 2007 Pp:105-111`

Amado Salvador Peña y Joaquín Hinojosa del Val
Perspectivas actuales en enfermedad inflamatoria intestinal. Prevención de recurrencias postquirúrgica. ¿Cuándo y cómo?
En “Hacia la integración en el tratamiento de las enfermedades digestivas”.
I Jornada Médico-Quirúrgica Hospital General Universitario de Valencia 4 Mayo 2007 Pp:113-117

                 918 kb pdf

Peña AS, Laine ML, Crusius JBA, Morré SA, van der Velden U, Lessmann F, van der Palen CJ, van Winkelhoff AJ, Loos BG
State of the art:Genetics and Genomics: Implications for Clinical Practice.
Editors: Adler G, Fiocchi C, Vorobjev GI
In Falk 154: Inflammatory Bowel Disease - Diagnostic and Therapeutic Strategies 2007

ChapterPDF (471 kb)
 

Presentaion (1,5 mb)
 

 

Chapters - Books 2006


Editores: Drs. García Paredes, Taxonera Samsó y A.S. Peña

Avances en el manejo de la enfermedad de Crohn y colitis ulcerosa

ISBN: 978-84-95913-92-0
Formato: 170 x 240 mm.
Numero de páginas: 260
Encuadernación: Rústica cosida
Fecha de edición: 2006

Dirigido por los Drs. García Paredes, Taxonera Samsó de la Unidad de Enfermedad Inflamatoria Intestinal del Hospital Clínico San Carlos y el Dr. Peña Director Internacional de la misma unidad. Todos los temas que aquí se incluyen son de una “rabiosa” actualidad, como la introducción del IBDchip como instrumento para intentar establecer el pronóstico en la Enfermedad de Crohn, los más recientes avances en las indicaciones de los tratamientos biológicos, el tratamiento de las fístulas con células madre, la leucocito aféresis tanto en España como en el extranjero, etcétera, etc., por lo que el interés previo estaba asegurado.

La presentación de casos clínicos para iniciar o abundar en cada capítulo, da a los mismos una agilidad y frescura que no se presentan cuando no limitamos a exponer de forma seriada y sistemática una serie de temas, que por nuestra forma de ser tienden a ser prolijos.
http://www.grupoaran.com/webN/libros.asp?S=6&IESP=2&IL=153&fechaPublicacion=01/10/2006

 

Autor: Peña AS
Actualizaciones. Enfermedad Celíaca. Tratamientos de Futuro ¿algo más que la dieta sin gluten?
Elsevier Science. Barcelona . GH Continuada 2006;5; pp: 272-276

  
                223 kb pdf

Book : Aféresis terapéutica
Editor: Fernando Anaya.
Publisher: Ediciones NORMA-CAPITEL.
ISBN: 84-8451-020-8

  1. González Lara V, Abreu García L, Peña Ramírez AS, Mendoza Hernández JL, Taxonera Samsó C, García-Paredes G, Marín Jiménez I.
    Chpater 23 AFT en enfermedad inflamatoria intestinal cronica.
    In: “Aferesis terapeutica.” Eds: Anaya F.
    Publisher: NORMA-CAPITEL; 293-305.
    PDF (6 mb)
     

Book - proceedings: Chlamydia trachomatis Infections.
Editors: A.S. Peña and S.A. Morré. Prous Science SA, Barcelona, Spain.
Drugs of Today 2006;42 Suppl A.

PDF (364 kb)
 
  1. Morré SA, Pannekoek Y, Ossewaarde JM.
    Over twenty-five years urogenital Chlamydia trachomatis research in The Netherlands
    In: “Chlamydia trachomatis Infections.” Eds: Peña AS and Morré SA. Prous Science SA, Barcelona, Spain.
    Drugs of Today 2006;42 Suppl A.
  2. Gorter AC, Segura ZE, Morré SA.
    Chlamydia trachomatis infections in Nicaragua: Preliminary results from a competitive voucher scheme to prevent and treat sexually transmitted infections and HIV among sex workers
    In:“Chlamydia trachomatis Infections.” Eds: Peña AS and Morré SA. Prous Science SA, Barcelona, Spain.
    Drugs of Today 2006;42 Suppl A.
  3. Vanrompay D, Lyons JM and Morré SA.
    Animal models to the study of Chlamydia trachomatis infections in the female genital tract
    In “Chlamydia trachomatis Infections.” Eds: Peña AS and Morré SA. Prous Science SA, Barcelona, Spain.
    Drugs of Today 2006;42 Suppl A.
  4. Morré SA, Spaargaren J, Ossewaarde JM, Land JA, Bax CJ, Oostvogel PM, Vanrompay D, Savelkoul PHM, Pannekoek Y, van Bergen JEAM, Fennema HSA, de Vries HJ, Crusius JBA, Peña AS, Ito JI, Lyons JM.
    Description of the ICTI consortium: an integrated approach to the study of chlamydia trachomatis infection.
    In “Chlamydia trachomatis Infections”. Eds: Peña AS and Morré SA. Prous Science SA, Barcelona, Spain.
    Drugs of Today 2006;42 Suppl A.

Chapters - Books 2005


Book - Gastroenterologia y hepatologia.
Editor: Nahum Méndez-Sánchez
Publisher: McGraw-Hill,Mexico City, Mexico

  1. Mónica Peñate and Amado Salvador Peña. Sistema inmunitario y aparato gastrointestinal. In: Section II. Chapter 3. Biología del Aparato Digestivo.
    PP 15-27. Editor: Nahum Méndez-Sánchez, Mexico City, Mexico, McGraw-Hill
  2. Juan Luis Mendoza, Raquel Lana Soto and Amado Salvador Peña. Enfermedad celiaca, esprue celiaco o enteropatía por sensibilidad al gluten In: Chapter 50
    P533-544. Editor: Nahum Méndez-Sánchez, Mexico City, Mexico McGraw-Hill

Book - proceedings: Falk Symposium Birmingham
Editors: Jewell DP, Colombel JF, Peña AS, Warren B.

  1. Peña AS and Marin-Jimenez, I. Budesonide in Ulcerative colitis.

Chapters - Books 2002


  1. Peña AS.
    Peptic ulcer and gastritis.

    In "Genetic Basis of Common Diseases 2nd Edition". Editors: Richard A. King, Jerome I. Rotter, Arno G. Motulsky. Publisher Oxford University Press, San Francisco, USA. pp 229 -249.
  2. Peñate M and Peña AS.
    Inmunología y tubo digestivo.
    En: Enfermedades del Aparato Digestivo y hepáticas. Ed: J. Berenguer Lapuerta. Editores Asociados Marina Berenguer, Julio Ponce, Martin Prieto y Teresa Sala. Pub. Elsevier Science, Spain 2002;pp 3-8

 

Proceedings 2001


García-Paredes J and Peña AS(Editors)(Spanish).
Aproximación a la enfermedad inflamatoria intestinal crónica a comienzos del nuevo siglo. Bases del tratamiento, nuevos avances y casos clínicos.

Drugs of Today 2001 Volume 37, Supl 8. Prous Science Barcelona 316 Pages.

García-Paredes J and Peña AS (Editors).
Treatment approaches in IBD at the turn of the century.

Drugs of Today 2001 Volume 37, Suppl. E. Prous Science Barcelona 289 Pages.

  1. Revuelta Blanco P, Peña AS.
    Patient Case : Corticosteroid-dependent ulcerative colitis. Immunosuppression, surgery or neither?

    Drugs of Today 2001;37( Suppl. E):193-196.
  2. Peña AS, Manoliu RA, Bloemena E.
    Patient case: Chronic IBD with panproctocolectomy. The patient's point of view.

    Drugs of Today 2001;37 (Suppl. E):279-284.

 

Proceedings - Books - Chapters 2000


Peña AS and Morton Vatn (Editors).
The Doctor in Focus.
proceedings of the Clinical Symposium Montreux February 2000. Drugs of Today 2000;36, Suppl. G Preface

  1. Peña AS, Manoliou RA, Bloemena E, Cohen A, lobo A, Rutgeerts P, Sachar D.
    Case presentation: mild to moderate Crohn's disease of the small and large bowel.
    Drugs of Today 2000
    ;36 Suppl G:103-107
  2. Peña AS.
    The doctor in focus. Farewell and messages.
    Drugs of Today 2000
    ;36 (suppl. G): 153-154
Chapters - Books
  1. Meuwissen SGM Peña AS
    Recent advances in the therapy for idiopathic inflammatory bowel disease.

    In: "IBD Year Book 2000". Eds Gabriele Bianchi Porro and Sandro Ardizzone. Publ Andrea Tencati Editore Milan, Italy pp 11-25.
  2. Nemetz A, Tulassay Z, Fehér J, Peña AS.
    Interleukin-1b gene polymorphisms as genetic markers in perforating and non-perforating Crohn's disease.
    In : "IBD at the end of its first century". Eds G. Rogler, F. Kullmann, P Rutgeerts, RB Sartor, J Schölmerich. Proceedings. Germany. Publ Kluwer Academic Publishers Dordrecht/Boston/London 2000; pp 12-21.
  3. Peña AS.
    Can we select patients for specific immunomodulatory therapy?
    In "IBD, Salicylates and other relevant therapies-4". Research and Clinical Forums 2000: 22(2):177-184
  4. Peña AS.
    Immunological Aspects of IBD.

    In "Treatment of digestive Diseases". Ed. L. Rodrigo. Publ Acción Médica SA. 2000;pp:137-145.
  5. Peña AS. 
    "El continuo aumento de la enfermedad crónica intestinal en España"

    Editorial Spanish. An Med Interna (Madrid) 2000; 17(6): 283-284
  6. Peña AS.
    Genetic mechanisms involved in IBD and Genetic Marker.

    In "Chronic Inflammatory bowel diseases. Progress and Controversies" Eds J. Holoman & J Glasa. Publisher Liver and Drug Foundation (Bratislava).Progress in Hepato-pharmacology 2000;5:33-39
  7. Peña AS, Meuwissen SGM, Falke ThJM, Cuesta MNA,  Hanauer SB, Rutgeerts P, Tremaine BW, Gassull MA,Cortot A and Cohen Z.
    Inflammatory bowel disease. A case presentation from Amsterdam with a panel discussion in Barcelona

    Prous Science Online
  8. Peña AS and Meuwissen SGM.
    Genetic of IBD can be used as a model in clinical gastroenterology
    .
    In: "IBD Year Book 2000". Eds Gabriele Bianchi Porro and Sandro Ardizzone. Publ Andrea Tencati Editore Milan, Italy pp 1-9.
  9. Peña AS.
    "Campos de Investigacíon"
    .
    In "La enfermedad celíaca" Documentos Técnicos de Salud Pública. Editors Arranz Leirado M, Polanco allué, I, Márquez Infante M. Diseño Andrea Tomasov comunicacíon adn diseño. Comunidad de Madrid, Spain. No 61;Chapter 14 2000 65-67.
  10. Pérez Pérez GI, Peña AS.
    Serology and the humoral, systemic and local immune response.
    In 'Helicobacter pylori infection in gastroduodenal lesions'. The second decade (Prous Science) 2000: 67-75 [Prous Science]
  11. van de Wal Y, Kooy Y, van Veelen P, Amons R, Mearin L, Peña S A, Drijfhout JW, Koning F.
    Characterization of antigens involved in coeliac disease.

    In: Mucosal Immunology and Ocular disease. Eds. Zierhut M and forrester JV. Aeolus Press BV, lisse, the Netherlands 2000; pp: 135-140